Aspirin in the Chemoprevention of Colorectal Neoplasia: An Overview
Year: 2011
Type: review
Abstract: Considerable evidence supports the effectiveness of aspirin for chemoprevention of colorectal cancer (CRC) in addition to its well-established benefits in the prevention of vascular disease. Epidemiologic studies have consistently observed an inverse association between aspirin use and risk of CRC. A recent pooled analysis of a long-term posttrial follow-up of nearly 14,000 patients from four randomized, cardiovascular disease prevention trials showed that daily aspirin treatment for about five years was associated with a 34% reduction in 20-year CRC mortality. A separate metaanalysis of nearly 3,000 patients with a history of colorectal adenoma or cancer in four randomized adenoma prevention trials showed that aspirin reduced the occurrence of advanced adenomas by 28% and any adenoma by 17%. Aspirin has also been shown to be beneficial in a clinical trial of patients with Lynch syndrome, a hereditary CRC syndrome; in those treated with aspirin for at least two years, there was a 50% or more reduction in the risk of CRC commencing five years after randomization and after aspirin had been discontinued. A few observational studies have shown an increase in survival among patients with CRC who use aspirin. Taken together, these findings strengthen the case for consideration of long-term aspirin use in CRC prevention. Despite these compelling data, there is a lack of consensus about the balance of risks and benefits associated with long-term aspirin use, particularly in low-risk populations. The optimal dose to use for cancer prevention and the precise mechanism underlying aspirin's anticancer effect require further investigation.
Source: Cancer Prevention Research
Authors: Andrew T. Chan, Nadir Arber, John Burn, Whay Kuang Chia, Peter Elwood, Mark A. Hull, Richard F. Logan, Peter M. Rothwell, Karsten Schrör, John A. Baron
Institutions: University of North Carolina at Chapel Hill, University of Nottingham, Tel Aviv University, Tel Aviv Sourasky Medical Center, University Hospital of Wales, St James's University Hospital, John Radcliffe Hospital, Massachusetts General Hospital, National Cancer Centre Singapore, Cardiff University, Newcastle University
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: Inflammation and Colorectal Neoplasia, NIHR Senior Investigator Award, G6252586019, Aspirin/Folate Prevention of Large Bowel Polyps, A randomised controlled trial of eicosapentaenoic acid (EPA) and/or aspirin for colorectal adenoma (or polyp) prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: The seAFOod polyp prevention trial
OpenAlex ID: W2138824201
